60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report sent to investors on Friday morning, MarketBeat reports. They currently have a $6.00 target price on the stock.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Wednesday, October 8th. Ascendiant Capital Markets lowered their price objective on 60 Degrees Pharmaceuticals from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Wednesday, September 3rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $4.50.

60 Degrees Pharmaceuticals Stock Down 22.2%

Shares of SXTP traded down $0.26 during midday trading on Friday, reaching $0.91. 398,327 shares of the stock were exchanged, compared to its average volume of 68,711. The company has a market cap of $3.73 million, a price-to-earnings ratio of -0.12 and a beta of 2.79. 60 Degrees Pharmaceuticals has a 12-month low of $0.85 and a 12-month high of $12.45. The firm has a 50 day simple moving average of $1.41 and a 200-day simple moving average of $1.78.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($1.21) by $0.55. The firm had revenue of $0.53 million during the quarter, compared to analyst estimates of $0.38 million. Research analysts expect that 60 Degrees Pharmaceuticals will post -5.09 earnings per share for the current fiscal year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.